High density lipoprotein future or investigational therapies: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | {{High density lipoprotein}} | ||
{{CMG}}; {{AE}} {{AN}}; {{RT}} | {{CMG}}; {{AE}} {{AN}}; {{RT}} | ||
Revision as of 20:20, 26 April 2013
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
High density lipoprotein future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of High density lipoprotein future or investigational therapies |
|
FDA on High density lipoprotein future or investigational therapies |
|
CDC on High density lipoprotein future or investigational therapies |
|
High density lipoprotein future or investigational therapies in the news |
|
Blogs on High density lipoprotein future or investigational therapies |
|
Risk calculators and risk factors for High density lipoprotein future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2]; Raviteja Guddeti, M.B.B.S. [3]
Overview
Promising future therapies include CETP inhibitors which are currently in the experimental phase. A combination therapy with statins and ACE inhibitors is also a safe option in patients with HDL levels who also share features with dysmetabolic syndrome. However, the preventive effects of these two drugs tend to be cumulative[1].
References
- ↑ Liem AH, Jukema JW, van Veldhuisen DJ (2003). "Secondary prevention in coronary heart disease patients with low HDL: which options do we have?". International Journal of Cardiology. 90 (1): 15–21. PMID 12821213. Unknown parameter
|month=ignored (help)